INTENSITY THERAPEUTICS INC Financials
This page shows INTENSITY THERAPEUTICS INC (INTS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Intensity Therapeutics remains a pre-revenue developer whose balance-sheet resets are funded by capital raises, not by operating cash generation.
Between FY2024 and FY2025, operating cash burn narrowed from-$15.2M to-$9.2M , closely tracking the smaller loss and signaling fairly direct earnings-to-cash translation for a business with little non-cash complexity. But cash still climbed to$11.9M because financing supplied$18.6M , so the stronger liquidity reflects external funding more than a self-funding operating model.
The cost structure is still development-led: FY2025 R&D spending of
Liquidity has been rebuilt since FY2022, with cash rising from
Financial Health Signals
INTENSITY THERAPEUTICS INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
INTENSITY THERAPEUTICS INC passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
INTENSITY THERAPEUTICS INC reported a net loss of $11.6M while operations used $9.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
INTENSITY THERAPEUTICS INC reported -$11.6M in net income in fiscal year 2025. This represents an increase of 28.7% from the prior year.
INTENSITY THERAPEUTICS INC earned -$8.56 per diluted share (EPS) in fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
INTENSITY THERAPEUTICS INC held $11.9M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
INTENSITY THERAPEUTICS INC's ROE was -97.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 459.8 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
INTENSITY THERAPEUTICS INC invested $6.8M in research and development in fiscal year 2025. This represents a decrease of 35.4% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
INTS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| R&D Expenses | N/A | $6.8M-35.4% | $10.5M+119.3% | $4.8M-6.7% | $5.1M |
| SG&A Expenses | N/A | $5.2M-14.8% | $6.1M+72.3% | $3.5M+46.1% | $2.4M |
| Operating Income | N/A | -$12.0M+27.8% | -$16.6M-99.4% | -$8.3M-10.2% | -$7.5M |
| Interest Expense | N/A | N/A | $0-100.0% | $305K+272.0% | $82K |
| Income Tax | N/A | $0 | $0 | $0 | $0 |
| Net Income | N/A | -$11.6M+28.7% | -$16.3M-54.4% | -$10.5M-39.0% | -$7.6M |
| EPS (Diluted) | — | -$8.56 | -$29.24 | -$1.38 | -$2.22 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
INTS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|
| Total Assets | $14.1M+194.8% | $4.8M-72.3% | $17.3M+884.3% | $1.8M |
| Current Assets | $12.7M+277.9% | $3.4M-78.3% | $15.5M+965.7% | $1.5M |
| Cash & Equivalents | $11.9M+360.3% | $2.6M-69.7% | $8.6M+552.1% | $1.3M |
| Total Liabilities | $2.2M+19.3% | $1.9M-54.9% | $4.1M-75.5% | $16.9M |
| Current Liabilities | $2.1M+22.3% | $1.8M-55.7% | $4.0M-41.9% | $6.8M |
| Total Equity | $11.9M+307.0% | $2.9M-77.8% | $13.2M+187.2% | -$15.1M |
| Retained Earnings | -$78.4M-17.4% | -$66.8M-32.2% | -$50.5M-30.7% | -$38.7M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
INTS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$9.0M | -$9.2M+39.3% | -$15.2M-111.2% | -$7.2M-31.6% | -$5.5M |
| Investing Cash Flow | N/A | $0-100.0% | $6.4M+205.5% | -$6.0M | $0 |
| Financing Cash Flow | $16.3M | $18.6M+540.1% | $2.9M-85.8% | $20.5M+809.9% | $2.3M |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
INTS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|
| Return on Equity | -97.7%+459.8pp | -557.5%-477.4pp | -80.1% | N/A |
| Return on Assets | -82.3%+257.8pp | -340.1%-279.2pp | -60.9%+370.6pp | -431.5% |
| Current Ratio | 5.92+4.0x | 1.92-2.0x | 3.91+3.7x | 0.21 |
| Debt-to-Equity | 0.19-0.5x | 0.64+0.3x | 0.31 | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where INTENSITY THERAPEUTICS INC Ranks
Frequently Asked Questions
Is INTENSITY THERAPEUTICS INC profitable?
No, INTENSITY THERAPEUTICS INC (INTS) reported a net income of -$11.6M in fiscal year 2025.
What is INTENSITY THERAPEUTICS INC's return on equity (ROE)?
INTENSITY THERAPEUTICS INC (INTS) has a return on equity of -97.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is INTENSITY THERAPEUTICS INC's operating cash flow?
INTENSITY THERAPEUTICS INC (INTS) recorded an outflow of $9.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are INTENSITY THERAPEUTICS INC's total assets?
INTENSITY THERAPEUTICS INC (INTS) had $14.1M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does INTENSITY THERAPEUTICS INC spend on research and development?
INTENSITY THERAPEUTICS INC (INTS) invested $6.8M in research and development during fiscal year 2025.
What is INTENSITY THERAPEUTICS INC's current ratio?
INTENSITY THERAPEUTICS INC (INTS) had a current ratio of 5.92 as of fiscal year 2025, which is generally considered healthy.
What is INTENSITY THERAPEUTICS INC's debt-to-equity ratio?
INTENSITY THERAPEUTICS INC (INTS) had a debt-to-equity ratio of 0.19 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is INTENSITY THERAPEUTICS INC's return on assets (ROA)?
INTENSITY THERAPEUTICS INC (INTS) had a return on assets of -82.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is INTENSITY THERAPEUTICS INC's cash runway?
Based on fiscal year 2025 data, INTENSITY THERAPEUTICS INC (INTS) had $11.9M in cash against an annual operating cash burn of $9.2M. This gives an estimated cash runway of approximately 15 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is INTENSITY THERAPEUTICS INC's Piotroski F-Score?
INTENSITY THERAPEUTICS INC (INTS) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are INTENSITY THERAPEUTICS INC's earnings high quality?
INTENSITY THERAPEUTICS INC (INTS) reported a net loss of $11.6M while operations used $9.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.